Paul Choi

“Good afternoon and congratulations on the data presentation at the plenary and the New England Journal article. I want to ask maybe Dr. Barrett first, I guess, now that we've seen the detailed data here as well as longer-term follow-up for drugs in this class, APRIL and APRIL-RAF inhibitors.”

“As you think about your commercialization efforts over the coming year, you'll be launching in symptomatic OHCM, frontline OHCM, and then NHCM, which is a lot of data to put in front of doctors.”

“I want to ask on Stellar 304 and timing, do you think this is something that might be able to make a major medical meeting this year? And just any sort of, you know, updated precision on data timing that you could offer would be great.”

“First, on the pipeline, you would expect to enroll tumor types in the HPK1, the greater program, similar to what we've seen from the HPK1 inhibitors like gastric, lung, anything there would be helpful.”